DRNA : Summary for Dicerna Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets closed

Dicerna Pharmaceuticals, Inc. (DRNA)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.04+0.10 (+3.40%)
At close: 4:00 PM EST
People also watch:
CNCEGNCAQUREEPZMAKBA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close2.94
Open2.93
Bid2.72 x 200
Ask4.96 x 800
Day's Range2.90 - 3.07
52 Week Range2.69 - 15.93
Volume119,245
Avg. Volume292,752
Market Cap63.09M
BetaN/A
PE Ratio (TTM)-1.07
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wire24 days ago

    Dicerna to Present at the Stifel 2016 Healthcare Conference

    Dicerna Pharmaceuticals, Inc. , a leading developer of investigational RNA interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Stifel 2016 Healthcare Conference on Wednesday, November 16, 2016, from 3:45-4:25 p.m.

  • Associated Press26 days ago

    Dicerna Pharmaceuticals posts 3Q loss

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 68 cents. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • Business Wire26 days ago

    Dicerna Reports Third Quarter 2016 Financial and Operational Results

    Dicerna Pharmaceuticals, Inc. , a leading developer of investigational RNA interference therapeutics, today reported financial and operational results for the third quarter ended September 30, 2016.